Dig Dis Sci: 晚期慢性肝病患者肝静脉压力梯度≤10mmHg与临床结果相关

2022-02-25 MedSci原创 MedSci原创

肝静脉压力梯度 肝静脉压力梯度(HVPG):经颈静脉插管测定肝静脉锲入压与游离压,两者之差即为HVPG,反映门V压力的大小。正常HVPG10mmHg则为门静脉高压。

肝硬化的临床病程主要由门静脉高压的进行性加重、高动力循环、细菌易位和全身炎症的激活决定。临床失代偿(CD)与这些机制的进展有关,可以通过血流动力学或临床特征来识别。CD 定义为出现静脉曲张出血、腹水、黄疸或脑病中的至少一种,每年发生率为 4-12%。确定 CD 的预测因子很重要,因为肝硬化中的死亡与 CD 的发展显著有关。众所周知,腹水、静脉曲张和静脉曲张出血的发展需要肝静脉压力梯度(HVPG)> 10mmHg(定义为临床上显着的门静脉高压症,CSPH)。HVPG 从基线降低 10-20% 或降至 <12 mmHg可能可以降低死亡或肝移植的风险。在本研究中,研究人员旨在判断 HVPG≤10 mm Hg 肝硬化患者的自然病程、CD 模式和临床结果。

 

研究人员将患有晚期慢性肝病 (aCLD) [组织学肝硬化 ( n =196) 或肝硬度测量 (LSM) > 15 kPa ( n = 65)] 和 HVPG 6-10 mmHg 的患者纳入本项研究。主要观察目标是研究他们的自然病程的变化和CD 模式的差异。为此,研究人员还分析了就诊时 CD 的预测因素以及对卡维地洛的反应差异。

 

在 HVPG 6-10 mmHg 的 261 名患者中,129 名(49.4%)在首次就诊时患有CD;最常见的 CD 表现是腹水 ( n = 77) 和黄疸 ( n = 65)。基线 HVPG ≥ 8 mmHg 与更大的 CD 风险独立相关 [HR:1.7;p =0.002,AUROC:0.85(95%CI-0.81–0.91)]。14.4% 的代偿期患者会出现新 CD症状(中位持续时间为 23.1 个月)。尽管基线 HVPG 相当,但发生新 CD 的患者在随访中具有更高的 HVPG(15.3±3.7 VS 8±2.1 mmHg;p < 0.001)。基线 LSM > 26.6 kPa、门体分流和血清白蛋白独立预测新 CD。对卡维地洛的总体 HVPG 反应(n = 60) 为 23.3%,与基线 CD 和 HVPG 无关。

图:肝静脉压力梯度的ROC曲线

 

本项研究结果证实近一半 HVPG 6-10 mmHg 的患者患有 CD。降低 HVPG≥8 mmHg 患者门静脉压力的干预措施可能会改善长期预后。

原始出处:

Ankur Jindal. Et al. Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient ≤ 10 mm Hg. Digestive Diseases and Sciences.2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013818, encodeId=861b2013818c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 23 01:53:03 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898889, encodeId=fba018988896f, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Oct 11 09:53:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017998, encodeId=07aa201e998ab, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Aug 07 21:53:03 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698346, encodeId=170216983461d, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Jan 03 02:53:03 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197296, encodeId=1bb9119e296af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368a5587157, createdName=ms3000002059832501, createdTime=Fri Feb 25 19:55:48 CST 2022, time=2022-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013818, encodeId=861b2013818c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 23 01:53:03 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898889, encodeId=fba018988896f, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Oct 11 09:53:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017998, encodeId=07aa201e998ab, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Aug 07 21:53:03 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698346, encodeId=170216983461d, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Jan 03 02:53:03 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197296, encodeId=1bb9119e296af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368a5587157, createdName=ms3000002059832501, createdTime=Fri Feb 25 19:55:48 CST 2022, time=2022-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013818, encodeId=861b2013818c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 23 01:53:03 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898889, encodeId=fba018988896f, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Oct 11 09:53:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017998, encodeId=07aa201e998ab, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Aug 07 21:53:03 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698346, encodeId=170216983461d, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Jan 03 02:53:03 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197296, encodeId=1bb9119e296af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368a5587157, createdName=ms3000002059832501, createdTime=Fri Feb 25 19:55:48 CST 2022, time=2022-02-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013818, encodeId=861b2013818c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 23 01:53:03 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898889, encodeId=fba018988896f, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Oct 11 09:53:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017998, encodeId=07aa201e998ab, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Aug 07 21:53:03 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698346, encodeId=170216983461d, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Jan 03 02:53:03 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197296, encodeId=1bb9119e296af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368a5587157, createdName=ms3000002059832501, createdTime=Fri Feb 25 19:55:48 CST 2022, time=2022-02-25, status=1, ipAttribution=)]
    2023-01-03 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013818, encodeId=861b2013818c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 23 01:53:03 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898889, encodeId=fba018988896f, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Oct 11 09:53:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017998, encodeId=07aa201e998ab, content=<a href='/topic/show?id=41ab81258fb' target=_blank style='color:#2F92EE;'>#肝病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81258, encryptionId=41ab81258fb, topicName=肝病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Aug 07 21:53:03 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698346, encodeId=170216983461d, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Jan 03 02:53:03 CST 2023, time=2023-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197296, encodeId=1bb9119e296af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368a5587157, createdName=ms3000002059832501, createdTime=Fri Feb 25 19:55:48 CST 2022, time=2022-02-25, status=1, ipAttribution=)]
    2022-02-25 ms3000002059832501

    学习学习

    0

相关资讯

Nature:慢性肝病患者细胞存在频繁的趋同进化

最近,研究人员分析了34个肝脏样本中1,590个基因组的体细胞突变,包括健康对照组、酒精相关肝病和非酒精性脂肪肝。

肝脏磁共振人工智能取得重大突破,“数字肝”全面提升诊断水平

肝病影响着全球几亿人。据估计,中国超过五分之一的人群受到肝脏疾病的困扰,尤其是乙肝、丙肝、肝硬化、肝癌、非酒精性脂肪肝、酒精性肝病和药物性肝损伤,

“神药”他汀再发威:不止抑制多种肝病进展,还可降低肝癌发生率!

Clinics in Liver Disease:他汀类药物有望抑制肝病的进展

《2021年亚太肝病学会临床实践指南:与免疫抑制治疗相关的HBV再激活》摘译

20世纪70年代,HBV再激活(HBV reactivation,HBVr)在HBs Ag阳性和HBs Ag阴性但抗-HBs阳性的骨髓增生性和淋巴细胞增生性疾病患者中首见报道。

Hepatology: 肝功能不全患者缺乏肝再生蛋白会促进非酒精性脂肪性肝炎和纤维化的发生

肝再生(ALR)蛋白(由生长因子ERV1同源基因编码)的增强剂在肝脏中高表达,主要在肝细胞中,并在细胞质,细胞核和线粒体中发现。